Trial Profile

An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin (Primary) ; Balstilimab (Primary) ; Botensilimab (Primary) ; Celecoxib (Primary) ; Chloroquine (Primary) ; Cisplatin (Primary) ; Famotidine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Acronyms The Seven Trial

23 Apr 2025 According to an Agenus media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 -June 3 in Chicago, Illinois.
13 Jan 2025 Planned number of patients changed from 12 to 18.
13 Jan 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com